Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vivaldi Biosciences Inc.

https://www.vivaldibiosciences.com/

Latest From Vivaldi Biosciences Inc.

Pacts In Medtech: Amarantus And Todos Form Breakthrough Diagnostics Inc.; Edwards Teams Up With Bay Labs To Find Heart Disease

Derived from Strategic Transactions, Informa's premium source for tracking life-sciences deals, the bimonthly Pacts In Medtech feature highlights notable technology alliances, R&D partnerships and commercial collaborations. This edition covers industry pacts that were sealed in November and December 2018.

Pacts in Medtech Deals

Vaccines Chess Game Continues With Baxter Sale To Pfizer

Pfizer, which saw 13% growth in its global vaccines business during the second quarter, pays $635 million to buy a pair of vaccines from Baxter. The meningitis and encephalitis vaccines, sold mainly in Europe, are expected to generate combined sales of about $300 million this year.

BioPharmaceutical Deals

Deals Shaping The Medical Industry, November 2013

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced September through October 2013.

BioPharmaceutical Medical Device

BioNotebook: Dyax, MacroGenics, Vivaldi and Rexahn

Dyax prices $60m offering; MacroGenics surges in first day of trading; Vivaldi acquires vaccine assets; and Rexahn licenses academic drug delivery platform.

Infectious Diseases Cancer
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Drug Discovery Tools
  • Other Names / Subsidiaries
    • Vivaldi Biosciences, Inc.
UsernamePublicRestriction

Register